<DOC>
	<DOCNO>NCT02570139</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy investigational product ( 3M™ Cavilon™ Advanced High Endurance Skin Protectant ) treatment incontinence associate dermatitis .</brief_summary>
	<brief_title>Clinical Study Assess New Barrier Film 's Ability Provide Skin Protection Against Incontinence &amp; Allow Healing</brief_title>
	<detailed_description>The purpose study evaluate product performance new skin protectant formulate protect damage denude skin even presence exposure potentially damaging body fluid , liquid stool gastric fluid . The product expect intimately adhere damage denude skin provide good protection damage commonly use product moisture barrier paste , thereby make easy nursing staff cleanse skin incontinence episode , thus save time also material . The denuded site buttocks/thighs score skin loss degree redness . Over course time , skin protect , re-epithelizes . The skin improvement score change baseline time monitor .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Zinc Oxide</mesh_term>
	<mesh_term>Protective Agents</mesh_term>
	<criteria>Subjects may enrol study answer question yes . 1 . Is subject fullterm newborn ( 36 week great gestational age ) old ? 2 . Is subject facility provide nurse care 24 hour per day ? 3 . Does subject severe Category 2 IncontinenceAssociated Dermatitis red skin breakdown ( i.e . skin erosion denudation denudation skin alone ) ? 4 . Is subject willing photo take skin expose incontinence permit use photograph potential publication ? 5 . Is subject willing release right 3M use photo ? 6 . Is reasonable expectation subject remain facility least 7 day follow enrollment study ? 7 . Has subject , legally authorize representative , sign Institutional Review Boardapproved inform consent/assent document authorize use disclosure protect health information ? Subjects exclude participation study answer follow question yes . 1 . If female , subject pregnant breast feed give birth within 3 week precede screen visit ? 2 . Does subject know allergy acrylate cyanoacrylates ? 3 . Does subject Stage III , IV , unstageable , suspected deep tissue injury pressure ulcer area skin affect incontinence ? 4 . Does subject preexist skin disease area affect incontinence may make skin assessment study difficult ? 5 . Does skin area affected incontinence require treatment concomitant medication product ? 6 . Does subject active genital herpes infection ? 7 . Has subject receive antifungal powder area affect IAD within 24 hour prior enrollment ? 8 . Has subject receive cyanoacrylate base skin protectant ( Marathon ) within 72 hour prior enrollment ? 9 . Is facility unwilling discontinue use subject Dimethiconecontaining wipe area skin protectant product apply ? 10 . Is facility unwilling discontinue use subject Chlorhexidine Gluconate wipe area skin protectant product apply ? 11 . Does subject medical condition opinion investigator exclude him/her participate study ? 12 . Has subject enrol investigational study product apply propose study sit within 30 day screen visit ?</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>